Zobrazeno 1 - 10
of 1 332
pro vyhledávání: '"Drug Price"'
Publikováno v:
Risk Management and Healthcare Policy, Vol Volume 17, Pp 2201-2208 (2024)
Xingyuan Gao,1,2 Man Yu,3 Yuyang Sun,3 Tiansi Zhang,1 Xin Li,1,3,4 Lingli Zhang,5 Changqing Wang1 1School of Health Policy and Management, Nanjing Medical University, Nanjing, People’s Republic of China; 2Simcere Zaiming Pharmaceutical Co., Ltd., N
Externí odkaz:
https://doaj.org/article/feda7837a48b49d4a7cce09b775a8033
Autor:
Santos Rutschman, Ana1,2
Publikováno v:
Emory Law Journal. 2020, Vol. 70 Issue 2, p347-416. 70p.
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 17, Iss 1 (2024)
ABSTRACTBackground To reduce Medicare prescription drug expenditures, the 2022 Inflation Reduction Act (IRA) allows the Centers for Medicare & Medicaid Services (CMS) to directly negotiate with drug manufacturers on Medicare prices of high-expenditur
Externí odkaz:
https://doaj.org/article/48613d76179842769386dabc5fd08ca0
Publikováno v:
International Journal for Equity in Health, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background PCSK9 inhibitors are a novel class of lipid-lowering drugs that have demonstrated favorable efficacy and safety. Evolocumab and alirocumab have been added to China’s National Reimbursement Drug List through the National Drug Pri
Externí odkaz:
https://doaj.org/article/c1fc2a1363e54eedbc8d03a8165fcc82
Publikováno v:
BMC Public Health, Vol 24, Iss 1, Pp 1-12 (2024)
Abstract Background The National Drug Price Negotiation (NDPN) policy has entered a normalisation stage, aiming to alleviate, to some extent, the disease-related and economic burdens experienced by cancer patients. This study analysed the use and sub
Externí odkaz:
https://doaj.org/article/a7363caef76744de89081ea91580faf7
Autor:
Mello, Michelle M.1,2
Publikováno v:
Minnesota Law Review. Jun2018, Vol. 102 Issue 6, p2273-2305. 33p.
Autor:
Walsdorf, Alexander1
Publikováno v:
Minnesota Law Review. Jun2018, Vol. 102 Issue 6, p2497-2545. 49p.
Autor:
Xuechen Xiong, Zhaohua Huo, Shuai Zhou, Ge Bai, Shiying He, Yinan Zhou, Jing Jia, Jianchao Quan, Li Luo
Publikováno v:
Frontiers in Public Health, Vol 12 (2024)
BackgroundChina’s National Essential Medicines Policy (NEMP) has been implemented for over 15 years; yet empirical evidence on its long-term impacts is lacking, particularly in remote and rural regions. This study aims to assess the short-and long-
Externí odkaz:
https://doaj.org/article/572e582dd7454ebc9b4d92b9672cb875
Autor:
Manu Kanchan
Publikováno v:
IIMB Management Review, Vol 36, Iss 1, Pp 83-92 (2024)
The literature on the Indian pharmaceutical industry has examined the importance of product patents and the attempts policy has made to regulate them. However, it has not done the same for the question of brands. Our study addresses this gap. The Tar
Externí odkaz:
https://doaj.org/article/680489e615f249b2b602343fa9baa08e